JP2021189004A - キャリブレータ、複合体、及びIgA凝集体を測定する方法 - Google Patents
キャリブレータ、複合体、及びIgA凝集体を測定する方法 Download PDFInfo
- Publication number
- JP2021189004A JP2021189004A JP2020093435A JP2020093435A JP2021189004A JP 2021189004 A JP2021189004 A JP 2021189004A JP 2020093435 A JP2020093435 A JP 2020093435A JP 2020093435 A JP2020093435 A JP 2020093435A JP 2021189004 A JP2021189004 A JP 2021189004A
- Authority
- JP
- Japan
- Prior art keywords
- iga
- calibrator
- complex
- avidins
- lectin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 74
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 106
- 108090001008 Avidin Proteins 0.000 claims abstract description 86
- 235000020958 biotin Nutrition 0.000 claims abstract description 60
- 229960002685 biotin Drugs 0.000 claims abstract description 53
- 239000011616 biotin Substances 0.000 claims abstract description 53
- 239000003153 chemical reaction reagent Substances 0.000 claims description 82
- 108090001090 Lectins Proteins 0.000 claims description 64
- 102000004856 Lectins Human genes 0.000 claims description 64
- 239000002523 lectin Substances 0.000 claims description 64
- 239000000126 substance Substances 0.000 claims description 42
- 239000007790 solid phase Substances 0.000 claims description 33
- 238000002372 labelling Methods 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 238000011088 calibration curve Methods 0.000 claims description 8
- 102100033312 Alpha-2-macroglobulin Human genes 0.000 claims description 6
- 102100040510 Galectin-3-binding protein Human genes 0.000 claims description 5
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 5
- 102100034256 Mucin-1 Human genes 0.000 claims description 4
- 101710187168 Alpha-2-macroglobulin Proteins 0.000 claims 1
- 101710136034 Alpha-2-macroglobulin homolog Proteins 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 101000967904 Homo sapiens Galectin-3-binding protein Proteins 0.000 claims 1
- 239000000523 sample Substances 0.000 description 49
- 108010078791 Carrier Proteins Proteins 0.000 description 45
- 102000014914 Carrier Proteins Human genes 0.000 description 45
- 108010043166 wisteria lectin Proteins 0.000 description 36
- 239000000243 solution Substances 0.000 description 33
- 108010090804 Streptavidin Proteins 0.000 description 17
- 238000002156 mixing Methods 0.000 description 16
- 239000006249 magnetic particle Substances 0.000 description 13
- 238000005259 measurement Methods 0.000 description 12
- 239000003431 cross linking reagent Substances 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 208000010159 IgA glomerulonephritis Diseases 0.000 description 10
- 206010021263 IgA nephropathy Diseases 0.000 description 10
- 239000000539 dimer Substances 0.000 description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 8
- 150000001615 biotins Chemical class 0.000 description 8
- 239000007853 buffer solution Substances 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 5
- 238000003118 sandwich ELISA Methods 0.000 description 5
- 101710197901 Galectin-3-binding protein Proteins 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 101710186708 Agglutinin Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101710146024 Horcolin Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 101710189395 Lectin Proteins 0.000 description 2
- 239000007987 MES buffer Substances 0.000 description 2
- 101710179758 Mannose-specific lectin Proteins 0.000 description 2
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 2
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010038211 Vicia lectins Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000910 agglutinin Substances 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical group [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 2
- TYJOJLOWRIQYQM-UHFFFAOYSA-L disodium;phenyl phosphate Chemical compound [Na+].[Na+].[O-]P([O-])(=O)OC1=CC=CC=C1 TYJOJLOWRIQYQM-UHFFFAOYSA-L 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229920000620 organic polymer Polymers 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 108010076805 snowdrop lectin Proteins 0.000 description 2
- 108010048090 soybean lectin Proteins 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- AUTOLBMXDDTRRT-JGVFFNPUSA-N (4R,5S)-dethiobiotin Chemical compound C[C@@H]1NC(=O)N[C@@H]1CCCCCC(O)=O AUTOLBMXDDTRRT-JGVFFNPUSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000220487 Bauhinia Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- 241000234473 Hippeastrum Species 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical group C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 241001532689 Narcissus pseudonarcissus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010015078 Pregnancy-Associated alpha 2-Macroglobulins Proteins 0.000 description 1
- 240000006023 Trichosanthes kirilowii Species 0.000 description 1
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N Trioxochromium Chemical compound O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- 235000018907 Tylosema fassoglense Nutrition 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229910000423 chromium oxide Inorganic materials 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229940124272 protein stabilizer Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910000859 α-Fe Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
- G01N2333/42—Lectins, e.g. concanavalin, phytohaemagglutinin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4724—Lectins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
1.測定用試薬の調製
(1.1) 試料希釈用緩衝液(第1試薬)
試料希釈用緩衝液として、1%BSA含有10 mM HEPES(pH7.5)を調製した。
WFAレクチン(ベクター・ラボラトリーズ社)を20 mM PBS(pH7.5)に添加し、WFA含有溶液(WFA濃度2.5 mg/mL)を得た。このWFA含有溶液に、ビオチン基を有する架橋剤である5-(N-スクシンイミジルオキシカルボニル)ペンチルD-ビオチンアミド(Biotin-AC5-Osu、株式会社同仁化学研究所)を、WFA/架橋剤(モル比)が1/100となるように添加した。得られた溶液を25℃で90分間インキュベーションして、WFAと架橋剤とを反応させた。得られた反応産物をHPLCにより精製して、ビオチン化二量体WFAを得た。HPLCには、分離カラムとしてゲルろ過カラム(TSKgel G3000SWXL、東ソー株式会社)を用い、溶出溶媒としてPBS(pH6.5)を用いた。ストレプトアビジン結合磁性粒子を含む懸濁液として、HISCL R2試薬(シスメックス株式会社)を用いた。ビオチン化二量体WFAとHISCL R2試薬とを、ビオチン化二量体WFAの濃度が20μg/mLとなるように混合して反応させた。得られた反応産物を100 mM MES緩衝液(pH6.5)で3回洗浄し、二量体WFAを固定した磁性粒子(以下、「WFA固定化粒子」ともいう)を得た。
抗IgA抗体として、抗ヒトIgA抗体(SouthernBiotech)を用いた。この抗IgA抗体とウシ小腸由来ALP(オリエンタル酵母株式会社)とを、マレイミド架橋剤を用いて結合させ、アフィニティクロマトグラフィーにより精製して、ALP標識抗IgA抗体を含む溶液を得た。
測定用緩衝液として、HISCL R4試薬(シスメックス株式会社)を用いた。基質溶液として、ALPの化学発光基質であるCDP-Star(商標)(アプライドバイオシステムズ社)を含むHISCL R5試薬(シスメックス株式会社)を用いた。
(2.1) ビオチン基を有するIgAの調製
IgA単量体として、ヒトIgA(Native Human IgA protein、Abcam社)を用いた。ヒトIgAを20 mM PBS(pH7.5)に添加してIgA溶液を得た。このIgA溶液に架橋剤Biotin-AC5-Osu(株式会社同仁化学研究所)を、IgA/架橋剤(モル比)が1/100となるように添加した。得られた溶液を25℃で90分間インキュベーションして、ビオチン化IgAを得た。
キャリアタンパク質として、M2BP(シスメックス社調製品)、MUC1(シスメックス社調製品)及びα2M(シグマアルドリッチ)を用いた。各キャリアタンパク質を20 mM PBS(pH7.5)に添加して、キャリアタンパク質の溶液を得た。この溶液に架橋剤Biotin-AC5-Osu(株式会社同仁化学研究所)を、キャリアタンパク質/架橋剤(モル比)が1/100となるように添加した。得られた溶液を25℃で90分間インキュベーションして、ビオチン化キャリアタンパク質を得た。
ビオチン化IgAを含む溶液と、ストレプトアビジン(Streptavidin SQ、ロシュ・ダイアグノスティックス株式会社)を含む溶液とを混合し、室温で1時間静置して、ビオチン化IgAとストレプトアビジンとの複合体(以下、「IgA-Bio-STA-Bio-IgA」とも呼ぶ)を得た。
各ビオチン化キャリアタンパク質の溶液と、ビオチン化IgAを含む溶液とを混合した。得られた混合液と、ストレプトアビジン(Streptavidin SQ、ロシュ・ダイアグノスティックス株式会社)を含む溶液とを混合し、室温で1時間静置して、ビオチン化IgAとビオチン化キャリアタンパク質とストレプトアビジンとの複合体(0.2 mg/mL)を得た。以下、M2BPを含む複合体を「M2BP-Bio-STA-Bio-IgA」とも呼び、MUC1を含む複合体を「MUC1-Bio-STA-Bio-IgA」とも呼び、α2Mを含む複合体を「A2M-Bio-STA-Bio-IgA」とも呼ぶ。
上記の第1試薬から第5試薬を用いて全自動免疫測定装置HISCL(商標)5000(シスメックス株式会社)により、キャリブレータとして、M2BP-Bio-STA-Bio-IgA、MUC1-Bio-STA-Bio-IgA及びA2M-Bio-STA-Bio-IgAのそれぞれを測定した。HISCL-5000による測定手順は、次のとおりであった。キャリブレータ(30μL)と第1試薬(100μL)とを混合した後、第2試薬(30μL)を添加した。得られた混合液中の磁性粒子を集磁して上清を除き、HISCL洗浄液(300μL)を加えて磁性粒子を洗浄した。上清を除き、磁性粒子に第3試薬(100μL)を添加して混合した。得られた混合液中の磁性粒子を集磁して上清を除き、HISCL洗浄液(300μL)を加えて磁性粒子を洗浄した。上清を除き、磁性粒子に第4試薬(50μL)及び第5試薬(100μL)を添加して、化学発光強度を測定した。対照として、ストレプトアビジン(STA)及び各ビオチン化キャリアタンパク質(M2BP-Bio、MUC1-Bio及びA2M-Bio)を同様に測定した。測定値(シグナルカウント)を表1に示す。
キャリブレータとして、M2BP-Bio-STA-Bio-IgA、MUC1-Bio-STA-Bio-IgA、A2M-Bio-STA-Bio-IgA及びIgA-Bio-STA-Bio-IgAを用いた。各キャリブレータを20 mM PBS(pH7.5)で5倍、25倍及び125倍に希釈したこと以外は、上記と同様にして測定した。測定値(シグナルカウント)を表2に示す。
11、21、31: 第1容器
12、23、34: 梱包箱
13、24、35: 添付文書
22、32: 第2容器
33: 第3容器
Claims (20)
- ビオチン基を有するIgA及びアビジン類を含み、試料中のIgA凝集体の濃度を取得するために用いられるキャリブレータ。
- 前記ビオチン基を有するIgAと前記アビジン類との複合体を含む試薬である請求項1に記載のキャリブレータ。
- 前記ビオチン基を有するIgAを含む試薬と、前記アビジン類を含む試薬とを含む試薬セットである請求項1項に記載のキャリブレータ。
- レクチンと結合する糖鎖及びビオチン基を有するポリペプチドをさらに含む請求項1に記載のキャリブレータ。
- 前記ビオチン基を有するIgAと前記アビジン類と前記ポリペプチドとの複合体を含む試薬である請求項4に記載のキャリブレータ。
- 前記ビオチン基を有するIgAを含む試薬と、前記アビジン類を含む試薬と、前記ポリペプチドを含む試薬とを含む試薬セットである請求項4項に記載のキャリブレータ。
- 試料中のIgA凝集体の濃度を取得するために用いられる、ビオチン基を有するIgAとアビジン類とを含む複合体。
- レクチンを用いて試料中のIgA凝集体を測定する方法であって、
ビオチン基を有するIgA及びアビジン類を含むキャリブレータを用いて、前記試料中のIgA凝集体の濃度を取得することを含む、前記方法。 - 前記キャリブレータが、前記ビオチン基を有するIgAと前記アビジン類との複合体を含む試薬である請求項8に記載の方法。
- 前記キャリブレータが、前記ビオチン基を有するIgAと前記アビジン類との複合体をそれぞれ含む複数の試薬を含む試薬セットであり、前記複数の試薬における前記複合体の濃度が互いに異なっている請求項8に記載の方法。
- 前記キャリブレータが、前記レクチンと結合する糖鎖及びビオチン基を有するポリペプチドをさらに含む請求項8に記載の方法。
- 前記ポリペプチドが、M2BP、MUC1及びα2Mからなる群より選択される少なくとも1の糖タンパク質の全部又は一部を含む請求項11に記載の方法。
- 前記キャリブレータが、前記ビオチン基を有するIgAと前記アビジン類と前記ポリペプチドとの複合体を含む試薬である請求項11又は12に記載の方法。
- 前記キャリブレータが、前記ビオチン基を有するIgAと前記アビジン類と前記ポリペプチドとの複合体をそれぞれ含む複数の試薬を含む試薬セットであり、前記複数の試薬における前記複合体の濃度が互いに異なっている請求項11又は12に記載の方法。
- 前記試料と、前記レクチンと、標識物質を含み且つ前記IgA凝集体に特異的に結合する捕捉体とを用いて、前記IgA凝集体の測定値を取得する工程と、
前記キャリブレータと、前記レクチンと、前記捕捉体とを用いて、前記複合体の測定値を取得する工程と、
前記IgA凝集体の測定値及び前記複合体の測定値から、前記試料中のIgA凝集体の濃度を取得する工程と
を含む請求項9、10、13及び14のいずれか1項に記載の方法。 - 前記IgA凝集体の濃度の取得工程において、前記複合体の測定値から検量線を作成し、前記検量線及び前記IgA凝集体の測定値に基づいて、前記試料中のIgA凝集体の濃度を取得する請求項15に記載の方法。
- 前記レクチンが固相に固定されている請求項8〜16のいずれか1項に記載の方法。
- 前記IgAがIgA1である請求項8〜17のいずれか1項に記載の方法。
- 前記レクチンが、WFA、HHL、GNA、NPA、SBA、VVA、BPL、TJA-II、PHA-L及びAOLからなる群から選択される少なくとも1のレクチンである請求項8〜18のいずれか1項に記載の方法。
- 前記レクチンがWFAである請求項8〜19のいずれか1項に記載の方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020093435A JP7473398B2 (ja) | 2020-05-28 | 2020-05-28 | キャリブレータ、複合体、及びIgA凝集体を測定する方法 |
CN202110549329.3A CN113740546A (zh) | 2020-05-28 | 2021-05-20 | 校准物、复合体、及对IgA凝集体进行测定的方法 |
US17/332,243 US11840578B2 (en) | 2020-05-28 | 2021-05-27 | Calibrator, complex, and method for measuring IgA aggregate |
EP21176402.2A EP3919513A1 (en) | 2020-05-28 | 2021-05-28 | Calibrator, complex, and method for measuring iga aggregate |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020093435A JP7473398B2 (ja) | 2020-05-28 | 2020-05-28 | キャリブレータ、複合体、及びIgA凝集体を測定する方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021189004A true JP2021189004A (ja) | 2021-12-13 |
JP7473398B2 JP7473398B2 (ja) | 2024-04-23 |
Family
ID=76522752
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020093435A Active JP7473398B2 (ja) | 2020-05-28 | 2020-05-28 | キャリブレータ、複合体、及びIgA凝集体を測定する方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US11840578B2 (ja) |
EP (1) | EP3919513A1 (ja) |
JP (1) | JP7473398B2 (ja) |
CN (1) | CN113740546A (ja) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE461616B (sv) | 1987-05-08 | 1990-03-05 | Biocarb Ab | Foerfarande och testsats vid diagnos av iga nefropati med bestaemning av fibronektin-iga-komplex |
JP2606722B2 (ja) | 1988-04-05 | 1997-05-07 | 栄治 石川 | 超高感度抗原物質の測定法 |
JP5031928B2 (ja) | 2009-07-14 | 2012-09-26 | 独立行政法人産業技術総合研究所 | 糖タンパク質の測定方法、肝疾患の検査方法、糖タンパク質定量用試薬および肝疾患病態指標糖鎖マーカー糖タンパク質 |
DE102011057019A1 (de) | 2011-12-23 | 2013-06-27 | Forschungszentrum Jülich GmbH | Standard zur Quantifizierung von pathogenen Aggregaten aus körpereigenen Proteinen |
WO2013172347A1 (ja) | 2012-05-14 | 2013-11-21 | 独立行政法人産業技術総合研究所 | IgA凝集体の検出方法およびIgA腎症の検査方法 |
JP6545960B2 (ja) * | 2014-02-27 | 2019-07-17 | シスメックス株式会社 | 標的物質の検出用試薬、検出方法および標的物質を検出するために用いられる担体ならびにその製造方法 |
-
2020
- 2020-05-28 JP JP2020093435A patent/JP7473398B2/ja active Active
-
2021
- 2021-05-20 CN CN202110549329.3A patent/CN113740546A/zh active Pending
- 2021-05-27 US US17/332,243 patent/US11840578B2/en active Active
- 2021-05-28 EP EP21176402.2A patent/EP3919513A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210371545A1 (en) | 2021-12-02 |
CN113740546A (zh) | 2021-12-03 |
US11840578B2 (en) | 2023-12-12 |
EP3919513A1 (en) | 2021-12-08 |
JP7473398B2 (ja) | 2024-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103380377B (zh) | 心肌肌钙蛋白的测定方法 | |
EP3315969B1 (en) | Method of detecting test substance by immune complex transfer method | |
US10191039B2 (en) | Human factor XIII as a normalization control for immunoassays | |
EP2235529A1 (en) | Determination of sflt-1:angiogenic factor complex | |
JP3863493B2 (ja) | イムノアッセイ法 | |
EP3415912A1 (en) | Analyte detection method and reagent kit for detecting analyte | |
JP5920945B2 (ja) | 可溶性インターロイキン−2受容体の測定方法及び測定用試薬 | |
JP2008102129A (ja) | 急性肺塞栓症用生化学マーカー | |
US20230160912A1 (en) | Method for immunoassay of amyloid beta in blood, and kit for same | |
JP4242499B2 (ja) | ホスホリルコリンを用いたcrpの測定方法 | |
JP7473398B2 (ja) | キャリブレータ、複合体、及びIgA凝集体を測定する方法 | |
JP7459045B2 (ja) | 標的物質の検出方法、標的物質の検出のための試薬、及び標的物質の検出のための試薬キット | |
JP2007225603A (ja) | 試料中の測定対象物の免疫測定方法および免疫測定試薬 | |
WO2023068249A1 (ja) | I型コラーゲン架橋n-テロペプチドの測定試薬、その調製方法、及びそれを用いた免疫測定方法 | |
JP2024046503A (ja) | 細胞外小胞に含まれるアルカリフォスファターゼの活性を測定する方法、キャリブレータ及び結合体 | |
Muratsugu et al. | Detection of biotin-binding immunoglobulin G in human sera using avidin-coated multiwell microplates | |
JP2006250862A (ja) | 妊娠中毒症の検知方法及び検知キット | |
AU2017232049A1 (en) | Method and apparatus for assisting diagnosis of risk of progression of diabetic nephropathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230424 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20230424 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240308 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240326 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240411 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7473398 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |